Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer

被引：4
|
作者：
Shiihara, Jun [1 ]
Ohyanagi, Fumiyoshi [1 ,2 ]
Amari, Hikari [1 ]
Toda, Minemichi [1 ]
Tahara, Hiroki [1 ]
Yuzawa, Motoi [1 ]
Maeda, Yuki [1 ]
Nomura, Motoko [1 ]
Mizushina, Yoshiko [1 ,3 ]
Nagai, Yoshiaki [1 ]
Ohta, Hiromitsu [1 ]
Yamaguchi, Yasuhiro [1 ]
机构：
[1] Jichi Med Univ, Clin Dept Internal Med, Div Resp Med, Saitama Med Ctr, Saitama, Japan
[2] Saitama Canc Ctr, Div Resp Med, Saitama, Japan
[3] Jichi Med Univ, Dept Med, Div Pulm Med, Shimotsuke, Tochigi, Japan
来源：
THORACIC CANCER | 2021年 / 12卷 / 17期
关键词：
alectinib; anaplastic lymphoma kinase; lung cancer; squamous cell cancer; MOLECULAR TESTING GUIDELINE; OPEN-LABEL; CRIZOTINIB; CARCINOMA; ASSOCIATION; GEFITINIB; PATHOLOGY; SELECTION; COLLEGE;
D O I：
10.1111/1759-7714.14092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lung cancers with anaplastic lymphoma kinase (ALK) rearrangements are highly sensitive to treatment with ALK tyrosine kinase inhibitors (TKIs). Due to the very low rate of patients with squamous cell carcinoma enrolled in clinical trials, the efficacy of ALK inhibitors in patients with ALK-rearranged squamous cell carcinoma in the lung remains unclear. Herein, we present the case of a 70-year-old female patient with squamous cell lung cancer harboring the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene. The patient was treated with the ALK-TKI alectinib as first-line regimen and achieved a dramatic response without severe adverse events, demonstrating alectinib as a therapeutic option for patients with ALK-positive squamous cell carcinoma.
引用
收藏
页码：2420 / 2423
页数：4
相关论文
共 50 条
  • [41] A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib
    Lim, Chloe A.
    Banyi, Norbert
    Tucker, Tracy
    Ionescu, Diana N.
    Melosky, Barbara
    [J]. CURRENT ONCOLOGY, 2022, 29 (02) : 848 - 852
  • [42] Concomitant genetic alterations predicted response to alectinib in patients with ALK-rearranged non-small cell lung cancer: A real word study in China
    Chen, X.
    Yu, X.
    Huang, J.
    Lai, J.
    Ding, L.
    Sheng, L.
    Ma, S.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1052 - S1052
  • [43] ALECTINIB IS ACTIVE IN CRIZOTINIB-RESISTANT ALK-REARRANGED NSCLC
    Gadgeel, S. M.
    Gandhi, L.
    Riely, G. J.
    Chiappori, A. A.
    West, H. L.
    Azada, M. C.
    [J]. CANCER DISCOVERY, 2014, 4 (10) : 1113 - 1113
  • [44] SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report
    Xia, G.
    Yu, S.
    Ni, J.
    Song, M.
    Zhang, J.
    Huang, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S526 - S527
  • [45] Complete Response to Alectinib Following Crizotinib in an ALK-Rearranged Metastatic Inflammatory Myofibroblastic Tumor
    Xavier, C.
    Canedo, F.
    Lima, F.
    Melo, R.
    Lima, L. G.
    Marin, J. F.
    Souza, C.
    Feher, O.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S661 - S662
  • [46] Targeting ALK-rearranged non-small-cell lung cancer: an update
    Sullivan, Ivana
    Planchard, David
    [J]. FUTURE ONCOLOGY, 2017, 13 (14) : 1213 - 1217
  • [47] Near complete response to ceritinib in a pediatric patient with metastatic ALK-rearranged lung adenocarcinoma
    Liu, Zuhui
    Liu, Maolin
    Hou, Xue
    [J]. LUNG CANCER, 2023, 176 : 140 - 143
  • [48] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
    Shaw, Alice T.
    Engelman, Jeffrey A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (26): : 2537 - 2539
  • [49] Sequential Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study
    Ito, Kentaro
    Hataji, Osamu
    Kobayashi, Hiroyasu
    Fujiwara, Atsushi
    Yoshida, Masamichi
    D'Alessandro-Gabazza, Corina N.
    Itani, Hidetoshi
    Tanigawa, Motoaki
    Ikeda, Takuya
    Fujiwara, Kentaro
    Fujimoto, Hajime
    Kobayashi, Tetsu
    Gabazza, Esteban C.
    Taguchi, Osamu
    Yamamoto, Nobuyuki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 390 - 396
  • [50] Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report
    Yao, Bin
    Han, Xue
    Pang, Linrong
    Xu, Caihong
    Liu, Sisi
    Cheng, Xiaochun
    Chen, Jun
    [J]. ONCOTARGETS AND THERAPY, 2021, 14 : 4329 - 4333
12345